for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

Mylan loses bid to dismiss EpiPen antitrust claims

Mylan Inc and a group of pharmacy benefit managers have lost a bid to dismiss a class action claiming the drugmaker paid kickbacks to the PBMs in order to drive up the price of its anti-allergy injection EpiPen, a federal judge has ruled.

U.S. District Judge Eric Tostrud in Minnesota ruled Friday that the plaintiffs, a group of drug distributors, had successfully pleaded their case that Mylan, Optum, CVS Caremark and Express Scripts engaged in a conspiracy under the Racketeer Influenced and Corrupt Organizations Act, and that Mylan violated the Sherman Act.

To read the full story on Westlaw Today, click here: bit.ly/38LJwGs

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up